Newsroom

CHATTANOOGA, Tenn.--(BUSINESS WIRE)--CBL Properties (NYSE:CBL) announced today that it has completed the refinancing of Fayette Mall, a dominant super-regional enclosed mall located in Lexington, Kentucky. The financing replaces the existing $98.6 million loan with a new $97.5 million, five‑year non-recourse CMBS loan with a fixed interest rate of approximately 7.25%. The new loan’s more favorable amortization structure results in approximately $5.0 million in additional cash flow to CBL. “This...

WESTLAKE, Ohio--(BUSINESS WIRE)--Prosperity Capital Advisors unveils unified entity, bringing five firms together under the Prosperity brand, building a destination advisory firm....

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 4/30/2026 Issue ¦ Rothschilds Continuation Finance PLC EUR 150,000,000 Index FRN due Perpetual     ISIN Number ¦ XS0197703118 ISIN Reference ¦ 19770311 Issue Nomin EUR ¦ 150000000 Period ¦ 5/5/2026 to 8/5/2026   Payment Date 8/5/2026 Number of Days ¦ 90 Rate ¦ 4.18   Denomination EUR ¦ 1000   ¦ 150000000   ¦       Amount Payable per Denomination ¦ 10.45   ¦ 1567500   ¦       Bank of New York     Rat...

DALLAS--(BUSINESS WIRE)--Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of Financial Assistance, Inc. to Cistern Capital Management. The acquisition closed April 2, 2026. Based in Bellevue, Washington, Financial Assistance, Inc. (FAI) is a financial services company providing recovery solutions for credit unions and banks. The firm specializes in compliant collections, legal-phase account management, and consum...

EDMONTON, Alberta--(BUSINESS WIRE)--Dickey's Barbecue expands in Edmonton’s Ellerslie area with fourth location opening featuring a Big Yellow Ticket giveaway May 15 through 17...

LONDON--(BUSINESS WIRE)--  Xtrackers (IE) plc Investment Company with Variable Capital Registered Office: 78 Sir John Rogerson's Quay, Dublin 2, Ireland Registration number: 393802 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Dublin, 30 April 2026 This announcement is to inform the shareholders of the sub-funds listed in the table below (each a Sub-Fund, and together the Sub-Funds) (the Shareholders) on behalf of the board of directors of the Compa...

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 4/30/2026 Issue ¦ Sutton and East Surrey Water plc GBP100,000,000 2.874% Index-Linked Notes due 2031     ISIN Number ¦ XS0126604726 ISIN Reference ¦ NA Issue Nomin GBP ¦ 100000000 Period ¦ 5/31/2026 to 11/30/2026   Payment Date 11/30/2026 Number of Days ¦ 183 Rate ¦ 6.934675   Denomination GBP ¦ 100000   ¦ 100000000   ¦       Amount Payable per Denomination ¦ 3467.34   ¦ 3467337.3   ¦       Bank of...

比利時根特--(BUSINESS WIRE)--(美國商業資訊)-- MRM Health是一家臨床階段生物製藥公司，致力於開發免疫介導疾病療法，旨在利用微生物組的力量恢復免疫平衡。該公司今天宣布，其領先的理性設計活體生物治療產品（LBP）候選藥物MH002已獲得美國食品藥物管理局（FDA）授予的「快速通道」資格，用於治療輕度至中度潰瘍性結腸炎（UC）。MH002是目前最先進的針對發炎性腸道疾病（IBD）特異性機制的LBP製劑，由六種特徵明確的共生菌株組成的理性設計的微生物菌叢構成。 FDA的「快速通道」旨在促進藥物研發，加快審批流程，以治療嚴重疾病並滿足未被滿足的醫療需求，其目的在於讓患者儘早獲得重要藥物。「快速通道」資格使企業得以加強與FDA的頻繁溝通，討論藥物研發計畫，並確保收集到支援藥物審批所需的適當資料。獲得「快速通道」資格的產品亦可能符合「加速核准」及「優先審查」的資格，且企業可分階段提交已完成的新藥申請（NDA）相關部分。 「FDA授予MH002快速通道資格，認可了這款前景廣闊的活體生物治療產品在滿足潰瘍性結腸炎患者對創新且更有效療法的巨大未滿足需求方面的潛力。這些患者對...

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 5/1/2026 Issue ¦ The Higher Education Securitised Investments (THESIS) GBP 27,300,000 Class A4 Mezzanine FRN due Perpetua     ISIN Number ¦ XS0085726585 ISIN Reference ¦ 429828AD8 Issue Nomin GBP ¦ 27300000 Period ¦ 4/10/2026 to 5/11/2026   Payment Date 5/11/2026 Number of Days ¦ 31 Rate ¦ 5.26807   Denomination GBP ¦ 100000   ¦ 27300000   ¦       Amount Payable per Denomination ¦ 45.42   ¦ 12399.99...

ベルギー・ヘント--(BUSINESS WIRE)--（ビジネスワイヤ） -- MRMヘルスは、マイクロバイオームの力を活用して免疫バランスの回復を目指す、免疫介在性疾患向け治療薬を開発する臨床段階のバイオ医薬品企業です。同社は、合理的に設計された主要な腸内細菌製剤（LBP）候補品である「MH002」が、軽度から中等度の潰瘍性大腸炎（UC）の治療を対象に、米国食品医薬品局（FDA）よりファストトラック指定を取得したことを発表しました。MH002は現在、炎症性腸疾患（IBD）に特有の機序を標的とする、最も開発が進んだ腸内細菌製剤（LBP）であり、特性が十分に明らかにされた6種類の常在菌株から成る、合理的に設計された微生物コンソーシアムで構成されています。 FDAのファストトラックは、重篤な疾患を治療し、アンメット・メディカル・ニーズに応える医薬品の開発を促進し、審査を迅速化することを目的とした制度です。その目的は、重要な医薬品をより早く患者に届けることにあります。ファストトラック指定により、医薬品の開発計画についてFDAと頻繁に協議し、医薬品承認を裏付けるために必要な適切なデータが収集...